Pfizer States That Its Vaccine Is Very Effective In Children Aged 5 to 11
Pfizer released data on Friday showing that its vaccine had a 90.7% effectiveness rate in preventing symptomatic Covid19 in a clinical study involving children aged 5 to 11. The company submitted the information to the Food and Drug Administration, which was due to release its analysis of the data later today. The children in the study received a dose of 10 micrograms, which was lower than the dose of 30 micrograms given to adults. The company said the dosage was safe and the study participants saw only mild side effects. The company released the data ahead of a meeting next week where F's expert advisers will decide whether to recommend the agency to authorize the vaccine for children in this age group. have alFederal regulators ready made the vaccine available for ages 12 and older. If F.clears the vaccine for children ages 5 to 11 - a move that could help protect more than 28 million people in the United States - the Centers for Disease Control and Prevention next month wi